- Data to be presented at International Shock Congress by sepsis thought
TORONTO, June 26 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced the presentation of data that demonstrates the combined clinical effectiveness of its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared diagnostic for the measurement of endotoxin, to identify patients with elevated endotoxin levels and to guide endotoxin reducing strategies, such as Toray Medical's therapeutic column, Toraymyxin(TM). The presentations will be made at a symposium entitled "Blood Purification in the Treatment of Sepsis," at the International Shock Congress in Cologne, Germany to be held from June 28-July 2.
"Several of the presentations at this important congress use data collected with Spectral's EAA(TM) and highlight the value of our product, both independently and in combination with anti-endotoxin therapies," said Dr. Paul Walker, President and CEO of Spectral. "Increasingly, EAA(TM) and Toray's therapeutic column, Toraymyxin(TM), which removes endotoxin from the bloodstream, are being recognized as a valuable combination for the diagnosis, treatment and monitoring of patients with severe sepsis."
The "Blood Purification in the Treatment of Sepsis" symposium will be held on July 1, from 8:30-10:00AM CEST. Speakers presenting data using EAA(TM) include Dr. David Klein of St. Michael's Hospital in Toronto, Canada, who will deliver a presentation entitled, "The Endotoxin Activity Assay (EAA(TM)) as a diagnostic tool for anti-endotoxin sepsis treatment". Dr. Eugen Faist of the University of Munich in Germany will speak about, "Endotoxemia and immune profiles of patients with acute sepsis due to major peritonitis". Information on the meeting, including the full scientific program, can be seen at http://www.shocksociety.org.
About Spectral Diagnosti
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved